TGFBI在头颈部鳞状细胞癌中的表达及其临床意义

doi:10.6040/j.issn.1673-3770.0.2022.459

摘要/Abstract

摘要： 目的探索转化生长因子β诱导基因(transforming growth faetor β indured gene, TGFBI)在头颈部鳞状细胞癌(head and neck souamous cell carcinoma, HNSCC)中的表达及其临床意义。方法采用NCBI数据库中的单细胞RNA-Seq测序数据分析TGFBI在免疫细胞中的表达,并通过Bulk RNA-Seq探索HNSCC肿瘤微环境的浸润情况。使用TCGA数据库分析TGFBI在HNSCC中的基因表达量及预后价值,并用临床标本验证。根据TGFBI表达量分组后HNSCC患者对靶向治疗和免疫治疗的响应进行TCGA数据评估,分析基因突变对TGFBI表达的影响。结果 TGFBI高表达于M2型巨噬细胞。TGFBI高表达与HNSCC患者不良预后相关。TGFBI低表达患者潜在响应免疫治疗,而TGFBI高表达的患者潜在响应靶向治疗。TP53突变与TGFBI高表达相关。结论 TGFBI可作为HNSCC患者生存与治疗反应的潜在生物标志物。

关键词: 头颈部鳞状细胞癌, 转化生长因子β诱导基因, 免疫浸润, 免疫治疗, 靶向治疗

Abstract: Objective To explore the expression of transforming growth factor β induced gene(TGFBI)in head and neck squamous cell carcinoma(HNSCC)and its clinical significance. Methods Single-cell RNA-Seq sequencing data from the NCBI database were used to analyze TGFBI expression in immune cells and Bulk RNA-Seq was used to explore the infiltration of the tumor microenvironment in HNSCC. The gene expression and prognostic value of TGFBI in HNSCC were analyzed using TCGA database and validated using clinical specimens. TCGA database were used to assess the response of HNSCC patients to targeted therapy and immunotherapy after grouping according to TGFBI expression and to analyse the effect of gene mutations on TGFBI expression. Results High TGFBI was expressed in M2 macrophages. High TGFBI was associated with poor prognosis in patients with HNSCC. Patients with low TGFBI expression may respond to immunotherapy, while patients with high TGFBI expression may respond to targeted therapy. Mutations in TP53 were significantly associated with high TGFBI expression. Conclusion There is some evidence that TGFBI can be used as a biomarker for predicting survival and treatment response in patients with HNSCC.

Key words: Head and neck squamous cell carcinoma, Transforming growth factor β induced gene, Immune infiltration, Immunotherapy, Targeted therapy

中图分类号:

R735.1

周一静,邹建银,易红良,吴红敏. TGFBI在头颈部鳞状细胞癌中的表达及其临床意义[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 85-95.

ZHOU Yijing, ZOU Jianyin, YI Hongliang, WU Hongmin. Expression of TGFBI in head and neck squamous cell carcinoma and its clinical significance[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 85-95.

参考文献

[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33. doi: 10.3322/caac.21654
[2] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview[J]. Int J Cancer, 2021. doi:10.1002/ijc.33588
[3] Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1): 92. doi:10.1038/s41572-020-00224-3
[4] Argiris A, Harrington KJ, Tahara M, et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck[J]. Front Oncol, 2017, 7: 72. doi:10.3389/fonc.2017.00072
[5] Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer[J]. N Engl J Med, 2008, 359(11): 1116-1127. doi:10.1056/NEJMoa0802656
[6] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival[J]. Lancet Oncol, 2010, 11(1): 21-28. doi:10.1016/S1470-2045(09)70311-0
[7] 卫亚楠, 陈曦. 局部晚期头颈部鳞状细胞癌的化疗及靶向进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(3): 118-124. doi:10.6040/j.issn.1673-3770.0.2020.276 WEI Yanan, CHEN Xi. Progress in chemotherapy and targeted drug therapy for locally advanced head and neck squamous cell carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(3): 118-124. doi:10.6040/j.issn.1673-3770.0.2020.276
[8] Steitz AM, Steffes A, Finkernagel F, et al. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced(TGFBI)and tenascin C[J]. Cell Death Dis, 2020, 11(4): 249. doi:10.1038/s41419-020-2438-8
[9] Pajares MJ, Agorreta J, Salvo E, et al. TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients[J]. Br J Cancer, 2014, 110(6): 1545-1551. doi:10.1038/bjc.2014.33
[10] Suzuki M, Yokobori T, Gombodorj N, et al. High stromal transforming growth factor β-induced expression is a novel marker of progression and poor prognosis in gastric cancer[J]. J Surg Oncol, 2018, 118(6): 966-974. doi:10.1002/jso.25217
[11] Patry M, Teinturier R, Goehrig D, et al. βig-h3 represses T-cell activation in type 1 diabetes[J]. Diabetes, 2015, 64(12): 4212-4219. doi:10.2337/db15-0638
[12] McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors[J]. Cell Syst, 2019, 8(4): 329-337.e4. doi:10.1016/j.cels.2019.03.003
[13] Kabutoya T, Ohmori T, Fujiwara T, et al. Combination therapy with an Xa inhibitor and antihypertensive agent improved anticoagulant activity in patients with nonvalvular atrial fibrillation: the hypertension and atrial fibrillation treated by rivaroxaban for the morning and night with sYnergy with calcium antagonists(HARMONY)study[J]. Clin Exp Hypertens, 2020, 42(4): 365-370. doi:10.1080/10641963.2019.1665678
[14] Cheng SJ, Li ZY, Gao RR, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells[J]. Cell, 2021, 184(3): 792-809.e23. doi:10.1016/j.cell.2021.01.010
[15] Tang ZF, Kang BX, Li CW, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis[J]. Nucleic Acids Res, 2019, 47(W1): W556-W560. doi:10.1093/nar/gkz430
[16] Sturm G, Finotello F, List M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data[J]. Methods Mol Biol, 2020, 2120: 223-232. doi:10.1007/978-1-0716-0327-7_16
[17] Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels[J]. PLoS One, 2014, 9(9): e107468. doi:10.1371/journal.pone.0107468
[18] Chen Y, Li ZY, Zhou GQ, et al. An immune-related gene prognostic index for head and neck squamous cell carcinoma[J]. Clin Cancer Res, 2021, 27(1): 330-341. doi:10.1158/1078-0432.CCR-20-2166
[19] Du KP, Zou JW, Wang BY, et al. A metabolism-related gene prognostic index bridging metabolic signatures and antitumor immune cycling in head and neck squamous cell carcinoma[J]. Front Immunol, 2022, 13: 857934. doi:10.3389/fimmu.2022.857934
[20] Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells[J]. Nature, 2018, 554(7693): 544-548. doi:10.1038/nature25501
[21] Lauss M, Donia M, Harbst K, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma[J]. Nat Commun, 2017, 8(1): 1738. doi:10.1038/s41467-017-01460-0
[22] Gide TN, Quek C, Menzies AM, et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy[J]. Cancer Cell, 2019, 35(2): 238-255.e6. doi:10.1016/j.ccell.2019.01.003
[23] Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer[J]. Nat Med, 2018, 24(9): 1449-1458. doi:10.1038/s41591-018-0101-z
[24] Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer[J]. Genome Res, 2018, 28(11): 1747-1756. doi:10.1101/gr.239244.118
[25] Lenze NR, Farquhar DR, Dorismond C, et al. Age and risk of recurrence in oral tongue squamous cell carcinoma: systematic review[J]. Head Neck, 2020, 42(12): 3755-3768. doi:10.1002/hed.26464
[26] 杨惠茹, 鲁海珍. 头颈部鳞状细胞癌免疫治疗预测指标及分子标志物的研究进展[J]. 中国肿瘤, 2022, 31(5): 387-393. doi:10.11735/j.issn.1004-0242.2022.05.A011 YANG Huiru, LU Haizhen. Advances on predictive indicators for prognosis of head and neck squamous cell carcinoma[J]. China Cancer, 2022, 31(5): 387-393. doi:10.11735/j.issn.1004-0242.2022.05.A011
[27] Yin WM, Yu XL, Kang XJ, et al. Remodeling tumor-associated macrophages and neovascularization overcomes EGFRT790M-associated drug resistance by PD-L1 nanobody-mediated codelivery[J]. Small, 2018, 14(47): e1802372. doi:10.1002/smll.201802372
[28] Chen YL, Zhang SY, Wang QZ, et al. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein[J]. J Hematol Oncol, 2017, 10(1): 36. doi:10.1186/s13045-017-0408-0
[29] Liu XL, Zhang CH, Wang XM, et al. Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer[J]. Endocr Relat Cancer, 2023, 30(3): e220221. doi:10.1530/ERC-22-0221
[30] Hlophe YN, Joubert AM. Vascular endothelial growth factor-C in activating vascular endothelial growth factor receptor-3 and chemokine receptor-4 in melanoma adhesion[J]. J Cell Mol Med, 2022, 26(23): 5743-5754. doi:10.1111/jcmm.17571
[31] Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial-mesenchymal transition[J]. Nat Rev Mol Cell Biol, 2020, 21(6): 341-352. doi:10.1038/s41580-020-0237-9
[32] Teng CL, Yu CT, Hwang WL, et al. Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells[J]. Ann Hematol, 2013, 92(3): 301-313. doi:10.1007/s00277-012-1627-7
[33] Halbach S, Hu ZH, Gretzmeier C, et al. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells[J]. Cell Commun Signal, 2016, 14: 6. doi:10.1186/s12964-016-0129-y
[34] Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring[J]. Am J Hematol, 2022, 97(9): 1236-1256. doi:10.1002/ajh.26642
[35] van Wigcheren GF, de Haas N, Mulder TA, et al. Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients[J]. Oncoimmunology, 2021, 10(1): 1935557. doi:10.1080/2162402X.2021.1935557
[36] Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers[J]. Mol Cancer Ther, 2017, 16(11): 2598-2608. doi:10.1158/1535-7163.MCT-17-0386
[37] Hayashi Y, Tsujii M, Kodama T, et al. p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth[J]. Carcinogenesis, 2016, 37(10): 972-984. doi:10.1093/carcin/bgw085
[38] Salmon H, Remark R, Gnjatic S, et al. Host tissue determinants of tumour immunity[J]. Nat Rev Cancer, 2019, 19(4): 215-227. doi:10.1038/s41568-019-0125-9

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed